Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Prevelance of Klebsiella Pneumonie in the Respiratory ICU

NCT07841288 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-06-25
Last updated
2026-10-02

Condition(s) studied

Klebsiella Pneumoniae

Investigational drug(s) / intervention(s)

No intervention (observational study)

No intervention (observational study): no intervention

Study summary

This observational study aims to determine the prevalence of Klebsiella pneumoniae isolates among respiratory specimens collected from adult patients admitted to the Respiratory Intensive Care Unit at Sohag University Hospital, and to describe their antimicrobial resistance profiles and associated clinical and epidemiological characteristics

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:Age ≥ 18 years Patients admitted to the Respiratory Intensive Care Unit Patients with Klebsiella pneumoniae isolated from respiratory specimens - Exclusion Criteria:Age \< 18 years Patients with other Gram-negative Enterobacteriaceae isolates \-

Primary outcome measure(s)

  • prevelance of klebsiella pneumoniae isolates — from june 2026 to june 2027
    prevalence/isolation rate of klebsiella pneumoniae among respiratory specimens collected from adult patients admitted to the respiratory intensive care at sohag university hospital

Trial sites (1)

FacilityCityRegionStatus
Sohag University Hospital Sohag Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07841288 on ClinicalTrials.gov ↗ ← All trials in Egypt